Area of research
Oncology · Epidemiology
Research interest
Research interests include Microscopic Colitis, Inflammatory Bowel Disease, Cancer Immunotherapy and Biomarkers, and Colorectal Cancer Treatments and Studies.
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Impact of <i>Helicobacter pylori</i> infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn’s Disease: A Systematic Review and Pooled Meta-analysis
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis
Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis